The Effect of Growth Hormone Treatment on Physical Performance Indices in Children With Idiopathic Short Stature.


Journal

Pediatric exercise science
ISSN: 1543-2920
Titre abrégé: Pediatr Exerc Sci
Pays: United States
ID NLM: 8909729

Informations de publication

Date de publication:
09 04 2021
Historique:
received: 28 03 2020
revised: 07 01 2021
accepted: 03 02 2021
pubmed: 11 4 2021
medline: 29 10 2021
entrez: 10 4 2021
Statut: epublish

Résumé

To examine the effect of growth hormone (GH) treatment on physical performance in children with idiopathic short stature and normal GH secretion. A total of 24 children participated in the study (13 GH-treated, 11 non-treated, aged 8-13 y, 11 males and 13 females, Tanner stage 1-2). Participants performed a battery of motor skill performance tests (Eurofit), as well as the Wingate anaerobic test. No statistically significant differences in any of the Eurofit physical fitness test results (eg, 20-m shuttle run 33.0 [15.1] vs 25.1 [21.0] laps in treated and nontreated participants, respectively, P = .25) or the Wingate anaerobic test were found between the groups (eg, peak power 5.0 [2.9] vs 3.9 [2.6] watts/kg in treated and nontreated participants, respectively, P = .2). Therapeutic usage of exogenous GH for pre and early pubertal children with idiopathic short stature and normal GH secretion was not associated with beneficial effects on physical performance indices. This suggests that the use of GH as a potential performance enhancing agent, in this age group, at least at commonly used doses, is not advantageous.

Identifiants

pubmed: 33837161
doi: 10.1123/pes.2020-0061
pii: pes.2020-0061
doi:
pii:

Substances chimiques

Human Growth Hormone 12629-01-5
Growth Hormone 9002-72-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

70-73

Auteurs

Adi Weinberg (A)

Tel Aviv University.

Nitzan Dror (N)

Tel Aviv University.

Katya Motin (K)

Tel Aviv University.

Michal Pantanowitz (M)

Tel Aviv University.

Dan Nemet (D)

Tel Aviv University.

Alon Eliakim (A)

Tel Aviv University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH